Matching adjusted indirect comparison of PFS & OS comparing ribociclib plus letrozole vs palbociclib plus letrozole as first-line treatment of HR+/HER2-ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2
Jhaveri K, O'Shaughnessy J, Fasching P, Cardoso F, Tolaney S, Hamilton E, Sharma VK, Biswas C, Haftchenary S, Pathak P, Rugo H (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: ELSEVIER SCI LTD
City/Town: OXFORD
Pages Range: S2-S3
Conference Proceedings Title: EUROPEAN JOURNAL OF CANCER
Event location: Barcelona
DOI: 10.1016/s0959-8049(22)01353-3
Authors with CRIS profile
Involved external institutions
Novartis AG
Switzerland (CH)
Sarah Cannon Research Institute (SCRI)
United States (USA) (US)
Dana–Farber Cancer Institute
United States (USA) (US)
Texas Oncology
United States (USA) (US)
University of California San Francisco (UCSF)
United States (USA) (US)
Champalimaud Foundation / Fundação Champalimaud
Portugal (PT)
Novartis Pharmaceuticals Canada Inc.
Canada (CA)
Memorial Sloan Kettering Cancer Center
United States (USA) (US)
Novartis Services, Inc.
United States (USA) (US)
Switzerland (CH)
Sarah Cannon Research Institute (SCRI)
United States (USA) (US)
Dana–Farber Cancer Institute
United States (USA) (US)
Texas Oncology
United States (USA) (US)
University of California San Francisco (UCSF)
United States (USA) (US)
Champalimaud Foundation / Fundação Champalimaud
Portugal (PT)
Novartis Pharmaceuticals Canada Inc.
Canada (CA)
Memorial Sloan Kettering Cancer Center
United States (USA) (US)
Novartis Services, Inc.
United States (USA) (US)
How to cite
APA:
Jhaveri, K., O'Shaughnessy, J., Fasching, P., Cardoso, F., Tolaney, S., Hamilton, E.,... Rugo, H. (2022). Matching adjusted indirect comparison of PFS & OS comparing ribociclib plus letrozole vs palbociclib plus letrozole as first-line treatment of HR+/HER2-ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2. In EUROPEAN JOURNAL OF CANCER (pp. S2-S3). Barcelona, ES: OXFORD: ELSEVIER SCI LTD.
MLA:
Jhaveri, K., et al. "Matching adjusted indirect comparison of PFS & OS comparing ribociclib plus letrozole vs palbociclib plus letrozole as first-line treatment of HR+/HER2-ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2." Proceedings of the 13th European Breast Cancer Conference (EBCC), Barcelona OXFORD: ELSEVIER SCI LTD, 2022. S2-S3.
BibTeX: Download